PHR

Phreesia, Inc.

Fundamental data last updated:November 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Healthcare Information Services

Exchange

NYSE

County of HQ

US

Next Earnings Date

12/02/2026

Business Summary

Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.

 


VALUATION

P/E

73.69

Market Cap ($M USD)

$787.68M

Forward P/E

43.59

PEG

0.28

PRICE TO SALES

1.55

PRICE TO BOOK

2.11

EV / EBITDA

13.95

5-Year Average P/E

Free Cash Flow Yield

9.84%

DCF Value

$45.12

Graham Number

$4.78

Price to FCF

10.16

EV to FCF

10.10

Earnings Yield

1.33%

FCF Yield

9.84%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.17

Next Year EPS Growth Estimate

$0.29

Next Year Revenue Growth Estimate

$515.67M

Return on Equity (ROE)

3.01%

FREE CASH FLOW

Operating Margin

3.19%

Debt-to-Equity

0.18

Piotroski F-Score

4

Altman Z-Score

1.08

Return on Invested Capital (ROIC)

3.18%

Current Ratio

1.76

Quick Ratio

1.76

Net Debt to EBITDA

-0.09

Interest Coverage

1.52

Gross Profit margin

63.55%

FCF PER SHARE

$1.25

REVENUE PER SHARE

$8.21

Gainseekers Quantitative Analysis

Summary

Phreesia, Inc. appears to be a classic case of market mispricing. With a DCF value significantly higher than its snapshot price, the stock seems undervalued. The Forward P/E ratio suggests future earnings growth potential, yet the Altman Z-score raises red flags about financial distress. Despite a minuscule earnings yield, the market’s optimism is evident in the consensus buy rating. The valuation metrics paint a picture of a company with potential upside, but not without its risks.

AI Exposure / Tech Reliance

Operating in the Medical - Healthcare Information Services industry, Phreesia is well-positioned to leverage AI and tech advancements. Its focus on healthcare information services aligns with the increasing digitization of healthcare. This positioning could enhance its adaptability and resilience in a rapidly evolving tech landscape.

The Bull Case

For the value or GARP investor, Phreesia offers compelling reasons to buy. The company's FCF Yield indicates efficient cash generation, while a Piotroski F-Score of 4 suggests moderate financial health. Despite a negative ROIC, the operating margin hints at potential for improvement. These metrics suggest that Phreesia could capitalize on its pricing power and operational efficiencies over time.

The Bear Case

However, the structural risks are glaring. The Price/Earnings ratio is astronomical, indicating potential overvaluation. The Altman Z-score is alarmingly low, signaling possible financial distress. Additionally, the negative operating margin and poor interest coverage ratio highlight operational inefficiencies. These factors could deter risk-averse investors, despite the low debt levels.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$12.14

Institutional Ownership %

1-Year Beta

0.84

Insider Buying % (6 Mo)

Distance to 52-Week High

77.94%

Distance to 52-Week Low

38.77%

EARNINGS SURPRISE %

-64.73%

50-DAY SMA

$11.20

200-DAY SMA

$10.79

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.